GRFS Stock Analysis: Buy, Sell, or Hold?
GRFS - Grifois, S.A.
$8.00
0.01 (0.13%)
▲
5d:
+2.83%
30d:
+6.1%
90d:
-1.36%
WAIT
LOW Confidence
Analysis Updated: Aug 21, 2026 12:00 AM ET
Earnings: Aug 24, 2026
0d
Get Alerted When GRFS Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 MIXED SIGNALS: GRFS shows conflicting indicators. Wait for confirmation before entering.
📊 MIXED SIGNALS: GRFS shows conflicting indicators. Wait for confirmation before entering.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$15.08
Based on 12.6% avg growth
INTRINSIC VALUE TODAY
$9.36
14.6% Margin of Safety
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 5.9x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: GRFS is currently trading at $8.00, which is considered extended relative to its 30-day fair value range of $7.45 to $8.08. The stock's valuation (Forward PE: 5.6) is in line with its historical norms (5.9). Remarkably, the market is currently pricing in an annual earnings decline of 1.7% over the next few years. This pessimistic expectation contrasts with the company's recent 32.9% earnings growth, suggesting potential undervaluation if the company simply maintains stability.
Technical Outlook: Technically, GRFS is in a downtrend. Immediate support is located at $7.68, while resistance sits at $8.38.
Market Sentiment: GRFS scores 60/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. Wall Street analysts see significant upside, with an average price target of $10.87 (+35.8%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, GRFS is in a downtrend. Immediate support is located at $7.68, while resistance sits at $8.38.
Market Sentiment: GRFS scores 60/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. Wall Street analysts see significant upside, with an average price target of $10.87 (+35.8%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$7.45 -
$8.08
Company Quality Score
49/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
61.9%
All Signals
- BEARISH: Price extended above range
- BULLISH: Strong technical setup (60/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 35.8% below Wall St target ($10.87)
- WARNING: Composite score 49/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$7.45 -
$8.08
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$7.68
Resistance Level
$8.38
Current Trend
Downtrend
Technical data as of
Aug 21, 2026
Fundamental Context
Forward P/E (Next Year Est.)
5.61
Wall Street Target
$10.87
(+35.8%)
Revenue Growth (YoY)
-0.9%
Earnings Growth (YoY)
32.9%
Profit Margin
6.1%
Valuation Discount vs History
-1.7% cheaper
PE vs Historical
5.6 vs 5.9
FAIR
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-1.7%
(market-implied from PE analysis)
1-Year Target
$7.86
(-2%)
2-Year Target
$7.73
(-3%)
3-Year Target
$7.60
(-5%)
3-Yr Target (if PE normalizes)
(PE: 6→6)
$7.99
(0%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 20.1, Growth: 21.1%)
$50.84
(+536%)
Base:
(SPY PE: 5.6, Growth: 21.1%)
$14.22
(+78%)
Bear:
(PE: 4.8, Growth: 21.1%)
$12.08
(+51%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (11x PE), but valuation improves significantly next year (6x PE) as earnings recover.
Trailing PE: 10.80 | Current EPS (TTM): $0.74
Bull Case
$16.93
(+112%)
Analyst growth 92.6%, PE expands to 11.9
Base Case
$15.39
(+92%)
Market implied 92.6%, PE stable at 10.8
Bear Case
$5.43
(-32%)
Severe decline -20.0%, PE contracts to 9.2
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 5.6 to 5.9
Stabilization Target:
$8.41
(+5.1%)
PE Expansion Potential:
+5.1%
Share & Embed Analysis
Last updated: August 24, 2026 12:07 AM ET
Data refreshes hourly during market hours. Next update: 1:07 AM
Data refreshes hourly during market hours. Next update: 1:07 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is GRFS showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Drug Manufacturers - General Stocks
Top-rated stocks in Drug Manufacturers - General by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
LLY
Eli Lilly and Company |
STRONG BUY
31 analysts |
$1315 | 37 SELL |
|
GILD
Gilead Sciences Inc |
BUY
30 analysts |
$157 | 34 SELL |
|
ABBV
AbbVie Inc |
BUY
28 analysts |
$277 | 41 HOLD |
|
BIIB
Biogen Inc |
HOLD
37 analysts |
$236 | 42 HOLD |
|
AMGN
Amgen Inc |
HOLD
32 analysts |
$388 | 38 SELL |
